Skip to the page

Data / Drug companies / Phlow Corporation

Phlow Corporation: 6 products in the FDA NDC directory, labeler code 81565

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Phlow Corporation (labeler code 81565) lists 6 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 6 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 11, 2023.

The request: Watch Phlow Corporation (FDA labeler code 81565): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
81565
Products in commercial distribution
6
Packages
6
Finished drugs by generic name
6
Prescription products
6
Over the counter products
0
Controlled substance products
Schedule II 1
Flagged as original packager
4 of 4 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
2
Earliest marketing start
August 1, 2019
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)350%
Generic drugs (ANDA)350%

Products by type

TypeProductsShare
Prescription drugs6100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution466.7%
Injection, powder, for solution116.7%
Injection116.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Fentanyl Citrate81565-205InjectionNew drug applications (NDA)January 11, 2023
Heparin Sodium81565-203Injection, solutionNew drug applications (NDA)March 7, 2022
Rocuronium81565-204Injection, solutionGeneric drugs (ANDA)February 8, 2022
Furosemide81565-201Injection, solutionNew drug applications (NDA)February 1, 2022
Dexamethasone Sodium Phosphate81565-202Injection, solutionGeneric drugs (ANDA)December 15, 2021
Vecuronium Bromide81565-206Injection, powder, for solutionGeneric drugs (ANDA)August 1, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.